

# ProFound AI<sup>®</sup>

## Artificial Intelligence Solutions for 2D Mammography & Digital Breast Tomosynthesis

### Benefits to the Facility

- Increases radiologists' average cancer detection rate
- Improves workflow efficiency
- Increases diagnostic confidence
- Optimal integration in multivendor environments

### Benefits to the Patient

- Assists in early cancer detection, which can lead to earlier treatment and improved outcomes
- Fewer false positives/unnecessary recalls
- Improves detection accuracy
- Provides peace of mind

### Precise, Powerful & Proven Technology to Improve Breast Cancer Detection.


iCAD, the market leader in multi-vendor, artificial intelligence (AI) detection solutions for breast cancer with more than a thousand installations worldwide, introduces: ProFound AI<sup>®</sup> 3<sup>rd</sup> generation.

ProFound AI is a clinically proven solution designed to amplify radiologists' diagnostic accuracy and performance reading 2D mammography and digital breast tomosynthesis (DBT).

### ProFound AI improves clinical confidence

This high-performing, concurrent-read, cancer-detection and workflow solution rapidly and accurately analyzes each image, or slice, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy, including in dense breasts. Similarly, ProFound AI allows radiologists to quickly confirm and validate the absence of cancer.

### ProFound AI for DBT is proven to offer superior clinical performance<sup>1</sup>



+8%  
in sensitivity



-7%  
in rate of recalls



-52.7% in reading  
time for radiologists

### ProFound AI for 2D Mammography is clinically proven to:


- Offer superior sensitivity up to 91.5 %<sup>2</sup>
- Accurately detect up to 48% interval cancers, according to a retrospective study.<sup>3</sup>

### NEW! ProFound AI 3rd generation performance<sup>4</sup>


The latest version of this software outperforms previous versions in sensitivity and specificity, with a significant reduction of false positive findings per image. Compatible with multiple mammography systems, ProFound AI offers critical insights for clinicians that can enhance clinical confidence and improve outcomes for women.



Up to 10% specificity  
performance improvement



Up to 4%  
in sensitivity



Up to 40%  
faster processing

Learn more about the ProFound  
impact our technology can offer  
to your practice.



# ProFound AI®

## for 2D Mammography & Digital Breast Tomosynthesis



### How does ProFound AI work?


The ProFound AI algorithm rapidly and accurately analyzes each individual image, or slice, and identifies potentially malignant lesions. Trained with one of the largest available image datasets, ProFound AI provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assists in clinical decision making and prioritizing caseloads.

### Certainty of Finding and Case Scores


Certainty of Finding lesion and Case Scores are assigned to each lesion and each case respectively. These are relative scores computed by the ProFound AI algorithm and represent the algorithm's confidence that a detection or case is malignant.

The scores are represented on a 0% to 100% scale. A higher score indicates a higher level of confidence in the malignancy of the detection or case. The Certainty of Finding and Case Scores serve as a guide to the interpreting radiologist to aid in determining if a suspicious finding or case needs further workup.


#### Examples of Certainty of Finding Scores for Soft Tissue Density and Calcification Detections




85% Certainty of Finding




48% Certainty of Finding



97% Certainty of Finding



43% Certainty of Finding



Case Score: 100%

### Platform

ProFound AI runs on the industry-leading PowerLook® server platform with NVIDIA® Graphical Processing Units (GPU), the latest in powerful GPU technology. PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, PACS, and image storage systems.

### About iCAD

iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions, with:

- More than 20 years of experience in Artificial Intelligence (AI)
- 50+ global patents
- More than 30 reference center partners around the world
- 2 AI products incorporating state-of-the-art deep learning technology built with one of the largest available datasets (ProFound AI for DBT, and ProFound AI for 2D Mammography)
- More than 7,000 installations around the world
- iCAD is a NASDAQ-listed company based in Nashua, NH, USA

#### References:

1. Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via <https://pubs.rsna.org/doi/10.1148/ryai.2019180096>
2. The value of 2D-AI-based CAD for second or third reading tested on 17,910 screening mammograms [RPS 702-4] by Sylvia H. HeyWang-Köbrunner MD, head of Referenzzentrum Mammographie München. (<https://event.crowdcompass.com/ecr2020/activity/78pY0IUG4N>)
3. Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance, up to 1% improvement in sensitivity with ProFound AI for Tomosynthesis and 4% improvement with ProFound AI for 2D mammography, and up to 40% faster processing on the new PowerLook platform.
4. iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Marked.

PowerLook (EC certificate #649468) and PowerLook Tomo Detection software (EC Certificate #672447), medical imaging post-processing software, are medical devices manufactured by iCAD, Inc. These medical devices are reserved for health professionals. These software programs have been designed and manufactured according to the EN ISO 13485 quality management system. Read the instructions in the User's Manual carefully before use. Manufacturer: iCAD, Inc. (USA). Medical devices Class IIa / Notified body: BSI. ©iCAD, Inc. / September 2021